期刊文献+

2,4-二甲基-5-甲酰基-1H-吡咯-3-甲酸的合成 被引量:1

Synthesis of 2,4-Dimethyl-5-formyl-1H-pyrrole-3-carboxylic Acid
下载PDF
导出
摘要 乙酰乙酸叔丁酯经系列反应得到的氨基酮与乙酰乙酸乙酯经Knorr反应得2,4-二甲基-3-乙氧羰基-1H-吡咯-5-羧酸叔丁酯,再经甲酰化、水解得抗肿瘤药舒尼替尼的重要中间体2,4-二甲基-5-甲酰基-1H-吡咯-3-甲酸,总收率约为44%。 2,4-Dimethyl-5-formyl-1H-pyrrole-3-carboxylic acid, the key intermediate of antitumor agent sunitinib, was synthesized from ethyl acetoacetate via Knorr reaction with keto-amino which prepared from tert-butyl acetoacetate to give tert-butyl 2,4-dimethyl-1H-pyrrole-3-carbethoxy-5-carboxylate, which was subjected to reaction with trifluoroacetic acid and triethyl orthoformate, followed by hydrolysis with an overall yield of about 44 %.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2007年第12期836-837,共2页 Chinese Journal of Pharmaceuticals
关键词 2 4-二甲基-5-甲酰基-1H-吡咯-3-甲酸 舒尼替尼 中间体 合成 2,4-dimethyl-5-formyl- 1H-pyrrole-3-carboxylic acid sunitinib intermediate synthesis
  • 相关文献

参考文献6

  • 1Kouraklis G, Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy [J]. Oncol Rep, 2006, 15 (2) : 489-494.
  • 2Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer[J]. J Clin Oncol, 2006, 24 (1) : 25-35.
  • 3Silverstein RM, Ryskiewicz E, Willard C, et al. Improved synthesis of 2-pyrrolealdehyde and of N-methyl-2- pyrrolealdehyde. Further studys of pyrrole alcohols [J]. J Org Chem, 1955, 20: 668-672.
  • 4Candy CF, Jones RA, Wright PH. Pyrrole studies. Part X V. Vilsmeier-Haack formylation of 1-substituted pyrroles [J]. J Chem Soc (C), 1970, 2563-2567
  • 5刘彪,林蓉,廖健宇,李子成,陈珂磊.舒尼替尼的合成[J].中国医药工业杂志,2007,38(8):539-542. 被引量:7
  • 6Cui JR, Ramphal Y, Liang CX, et al. 5-Aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors: WO, 02096361 [P]. 2002-12-05. (CA 2003, 138: 14005)

二级参考文献6

  • 1李进,郭晔,陆嘉德.转移性肾癌的靶向治疗[J].中国癌症杂志,2007,17(1):24-28. 被引量:4
  • 2Peng C-T,Miller TA,Li X-Y,et al.Pyrrole substituted 2-indolinone protein kinase inhibitors:US,2002/0156292[P].2002-10-24; WO,01/60814[P].2001-08-23.(CA 2001,135:195497)
  • 3Schnettler RA,Dage RC,Grisar JM.Pyrrole-3-carboxylate cardiotonic agents:US,4560700[P].1985-12-24.(CA 1986,105:114896)
  • 4Silverstein RM,Ryskiewicz EE,Willard C.2-Pyrrolealdehyde[J].Org Synth Coll Vol,1963,4:831-833.
  • 5Yen VQ,Buu-Ho NP,Xuong ND.Fluorinated isatins and some of their heterocyclic derivatives[J].Pharmazie,1958,23:1858-1861.
  • 6Soriano DS.Example of the Wolff-Kishner reduction procedure suitable for an undergraduate organic lab experiment:preparation of oxindole[J].J Chem Educ,1993,70 (4):332.

共引文献6

同被引文献18

  • 1ALFRED T, KARL H. tert-Butyl esters of pyrrole carboxylic acids [J]. ChemBer, 1954, 87(8):1167-1174.
  • 2SCHNETTLER RA, DAGE RG, GRISAR JM. Pyrrole-3-carboxylate cardiotonic agents: US, 1985/699607 A[ P]. 1985 -02 - 08.
  • 3SATTLER M, PRIDE YB, MA P, et al. A novel small molecule MET inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase [ J ]. Cancer Res, 2003, 63 (17) :5462 -5469.
  • 4CECCHI F, RABE DC, BOTTARO DP. Targeting the HGF/MET signaling pathway in cancer [ J ]. Eur J Cancer, 2010, 46 ( 7 ) : 1260 - 1270.
  • 5OSADA S, YOSHIDA K. Application of biological study for MET expression to cancer therapy [ J]. Anti-Cancer Agents Med Chem, 2010, 10(1) :58 -63.
  • 6COMOGLIO PM, GIORDANO S, TRUSOLINO L. Drug development of MET inhibitors: targeting oncogene addiction and expedience[J]. NatRev, 2008, 7(6):504-516.
  • 7KARAMOUZIS MV, KONSTANTINOPOULOS PA, PAPAVASSILIOU AG. Targeting MET as strategy to overcome crosstalk-related resistance to EGFR inhibitors[ J]. Lancet Oncol, 2009, 10 (7) :709 -717.
  • 8MA PC, JAGADEESWARAN R, JAGADEESH S, et al. Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer[J]. Cancer Res, 2005, 65(4) :1479 - 1488.
  • 9WANG XY, LE P, LIANG CX, et al. Potent and selective in- hibitors of the MET [ hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion [ J]. Mol Cancer Ther, 2003, 2 ( 11 ) : 1085 - 1092.
  • 10BERTHOU S, AEBERSOLD DM, SCHMIDT LS, et al. The MET kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants [ J ]. Oncogene, 2004, 23 (31 ) :5387 - 5393.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部